During Development. Interplay shall use diligent good faith efforts to deliver each Gold Candidate free of material Program Errors, and to provide Program Error Corrections for any material Program Errors identified by VUG in writing during VUG's testing of any Gold *** Terms represented by this symbol are considered confidential. These confidential terms have been omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission ("SEC") and have been filed separately with the SEC. Candidate of a PC Partner Product in accordance with SECTION 3 above. Interplay acknowledges and agrees that Interplay shall bear the sole cost and expense associated with such Program Error Corrections.
During Development. Interplay shall use diligent good faith efforts to deliver each Gold Candidate free of material Program Errors, and to provide Program Error Corrections for any material Program Errors identified by VUG in writing during VUG's testing of any Gold Candidate of a PC Partner Product in accordance with SECTION 3 above. Interplay acknowledges and agrees that Interplay shall bear the sole cost and expense associated with such Program Error Corrections. *** Terms represented by this symbol are considered confidential. These confidential terms have been omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission ("SEC") and have been filed separately with the SEC. Vivendi Universal Games, Inc. Page 9 Video Game Publishing Agreement
During Development. Interplay shall use diligent good faith efforts to deliver each Gold Candidate free of material Program Errors, and to provide Program Error Corrections for any material Program Errors identified by VUG in writing during VUG's testing of any Gold Candidate of a PC Partner Product in accordance with SECTION 3 above. Interplay acknowledges and agrees that Interplay shall bear the sole cost and expense associated with such Program Error Corrections.
During Development. In addition to the other responsibilities set forth in Section 2.4, in connection with Co-Development Activities for the Joint Development Territory, the JPT shall be responsible for: (i) coordinating and integrating the direction and objectives for Development activities for the Joint Development Territory related to Development for Co-Development Indications; (ii) monitoring and reporting on the competitive landscape for the Products for any Co-Development Indications for the Joint Development Territory; (iii) subject to the overview of the JSC, developing the strategy and plans for Development of Products within the Co-Development Activities (including regulatory strategies and strategies and plans for the Manufacture of Products for such Development purposes); (iv) reviewing and approving (as provided herein) the contents and timing of material Regulatory Filings and the protocol (and any material amendment thereof) for each clinical trial for a Product for any Co-Development Indications for the Joint Development Territory or other studies that are Co-Development Activities; (v) coordinating the exchange of Development information and Data relating to studies for Products for any Co-Development Indications or other studies that are Co-Development Activities and interactions with Regulatory Authorities in the Joint Development Territory; (vi) reviewing material agreements (generally an agreement with an expense above a certain threshold determined by the JSC) with Third Parties to be entered into by either or both Parties related to the Development of Products within the Co-Development Activities; and (vii) other matters related to the monitoring, review, coordination and approval of Development of Products within the Co-Development Activities. In addition, the JPT shall facilitate the exchange of information regarding the planning, conduct and progress of Development of Products for Exclusive Indications and for Co-Development Indications for outside the Joint Development Territory, and provide a forum for discussion and coordination of such Development activities with the Co-Development Activities.
During Development. If the Lead Development Party enters into a Partnering Agreement during the Collaboration Period, the Lead Development Party shall (in accordance with and without limiting Section 4.10) provide a copy of the Partnering Agreement to the Non-Lead within 5 business days after such agreement is executed. The Non-Lead shall have [*] days from receipt of the final, executed Partnering Agreement to notify the Lead Development Party in writing whether it will: (A) opt out of the Collaboration in the Partnered Territory, or worldwide, in accordance with Section 3.7(a)(ii) and receive royalties on Net Sales in the Partnered Territory, or worldwide if the opt-out is worldwide, at a rate selected from the table set forth in Section 7.6(b) based on the stage of Development when such opt-out becomes effective, but subject to any additional reductions in the applicable royalty rate that apply under Sections 6.3(a), 7.6(d), 7.6(e) and 7.6(g) of this Agreement; or (B) continue as the [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.. Non-Lead and continue to Share Development Costs and Licensing Revenue that the Lead receives during the Collaboration Period. If the Non-Lead fails to provide the Lead Development Party with written notice within the [*] day period, the Non-Lead is deemed to have elected to continue as the Non-Lead in accordance with clause (B).
During Development. Prior to the receipt of Regulatory Approval in a particular Collaborative Field in the U.S. Territory or the European Union, termination under this Section 17.3 in such Collaborative Field shall pertain to both the ROW Territory and the U.S. Territory and such termination shall become effective [****] after PDL’s receipt of Roche’s written termination notice. During the period between Roche’s termination notice and the effective date of such termination (the “Termination Notice Period”), the Parties shall continue to perform all of their obligations under this Agreement with respect to the affected Collaborative Field, including sharing Development Expenses and other costs required to be shared under this Agreement; provided, however, that no payments shall become due or payable for any development or commercialization events in the affected Collaborative Field that are first achieved during the applicable Termination Notice Period. Termination of this Agreement with respect to a Collaborative Field pursuant to this Section 17.3(a) shall have the following effects:
